Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD.

about

Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD.

Item

http://www.wikidata.org/entity/Q47677209

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD.

@en

Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD.

@nl

type

Item

label

Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD.

@en

Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD.

@nl

prefLabel

Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD.

@en

Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD.

@nl

P1476

Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD

@en

P2093

Maurizio Bonati

http://www.w3.org/2001/XMLSchema#string

P2860

ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents

Hallucinations and Other Psychotic Symptoms Associated With the Use of Attention-Deficit/Hyperactivity Disorder Drugs in Children

ADHD medications and risk of serious cardiovascular events in young and middle-aged adults.

The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders

Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis

Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents

Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.

Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.

Adverse drug reactions from psychotropic medicines in the paediatric population: analysis of reports to the Danish Medicines Agency over a decade.

A systematic review of the safety of lisdexamfetamine dimesylate.

P304

1335-1345

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14740338.2017.1389894

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Clavenna

Maurizio Bonati

P577

2017-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28984477

http://www.w3.org/2001/XMLSchema#string